1[1]Weick JK, Kopeeky K J, Appelbaum FR.et al. A randomized in vestigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patient with previously untreated aeute myeloid leukemia: a southwest oneology group study. Blood. 1996.1588(8): 2841.
2[2]Karanes C. Kopecky KJ. Head DR.et al. A phase Ⅲ eompmison of high dose Ara - C (HIDAC) versus HIDAC plus Mitoxantrone in the treatment of first relapsed of refractory acute myeloid leukemia:southwest oncology group study. Leuk Res. 1999, 23(9): 787.
3[3]Kern W.Braess J,Grotle-Metke A.et al.Combination of aclarubicin and etoposide for the treatment of advanced acute myeloid leukemia:results of a prospectiye mullicenter phase Ⅱ trial. German AML Cooperalive Group. Leukenia. 1998, 12 ( 10 ): 1522.
4[4]Morin MJ,Sartorelli AC.Inhibition of glycoprotein biosynthesis by the indtcers of HL-60 cell differentiation, aclacinomyein A and manellomycin. Cancer Res, 1984,44(7): 2807.
5[5]Wadler S,Fuks JZ,Wiernik PH. Phase Ⅰ and Ⅱ agents in cancer therapy: I. Anthraeyelines and relaled compounds. J Clin Pharma col, 1986,28(7) :491.